MedTrace Logo

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-10-07

No results posted yet for this study

Summary

The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.

Conditions

  • Thyroid Cancer
  • Thyroid Cancer, Follicular
  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Hurthle Cell Tumor
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Hurthle Cell Thyroid Neoplasia

Interventions

DRUG

Trametinib

2mg by mouth daily \*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube

DRUG

Dabrafenib

150 mg twice daily (OR at dose the patient previously tolerated)

DRUG

PDR001

400mg IV every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Alan L Ho, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2026-09-02
Completion
2026-09-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04544111 on ClinicalTrials.gov